InflaRx
Jena
Germany
Tel: 49-3641-508-180
107 articles about InflaRx
-
InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
6/5/2019
InflaRx reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.
-
InflaRx Reports First Quarter 2019 Financial & Operating Results
5/23/2019
InflaRx reported financial and operating results for the first quarter ended March 31, 2019.
-
InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe
5/14/2019
InflaRx today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801).
-
InflaRx Full Year 2018 Financial & Operating Results
3/28/2019
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1
-
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
2/27/2019
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers
-
Richard Brudnick to join InflaRx Board of Directors
2/14/2019
InflaRx N.V. announced that Mr. Richard Brudnick has been appointed, as interim Non-Executive Director to the Board of Directors of InflaRx N.V.
-
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
2/6/2019
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment
-
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
1/3/2019
- Jason Marks appointed Chief Legal Officer / General Counsel
-
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
12/19/2018
InflaRx N.V. today announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
-
InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results
11/26/2018
• Completion of patient recruitment in phase IIb trial in Hidradenitis Suppurativa • First patient dosed in phase II trial with IFX-1 in ANCA- associated vasculitis • Board of Directors appointment Jens Holstein, Chief Financial Officer of MorphoSys AG
-
InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa
11/8/2018
Trial Results Anticipated First Half 2019
-
InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing
10/30/2018
InflaRx N.V. today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).
-
InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors
9/21/2018
InflaRx N.V. announced today that Jens Holstein has been appointed as a new board member of InflaRx, serving as Non-Executive Director.
-
InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1
8/28/2018
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, will host an R&D Day on Hidradenitis Suppurativa (HS) and its scientific and clinical experience with its breakthrough anti-C5a monoclonal antibody IFX-1, on Friday, September 7 in New York City.
-
There are several recent announcements of German companies opening laboratories in the U.S.
-
InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa
3/8/2018
InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced enrollment of the first patient in its Phase IIb study with IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS).
-
InflaRx Presents at Two Scientific Conferences in February, 2018
2/1/2018
InflaRx N.V. will present data on IFX-1, an anti-C5a monoclonal antibody, at two international scientific conferences.
-
InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa
1/9/2018
The open IND will allow InflaRx to conduct a phase IIb study to determine efficacy and safety of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate or severe Hidradenitis Suppurativa.
-
The company announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share.
-
InflaRx Scores $55 Million To Push Lead Drug Into Phase II Trials
10/13/2017